Chlamydia infections constitute a major public health problem. Although multiple arms of the immune system participate in the control of Chlamydia in infected hosts, T lymphocytes are essential. This review focuses on the roles that CD8 + T cells may play in immunoprotection and immunopathology following recognition of Chlamydia-infected cells.
KeywordsChlamydia; CD8 + T cells
IntroductionMembers of the Chlamydiaceae family are obligate intracellular gram-negative bacteria that include the human pathogens Chlamydia trachomatis (Ct) and Chlamydia pneumoniae (Cpn). While Ct is responsible for ocular and sexually transmitted diseases that can result in blindness and infertility, Cpn is a common cause of upper respiratory infections and pneumonia and has been associated with several chronic inflammatory conditions such as atherosclerosis and chronic obstructive pulmonary disease (COPD) [1][2][3]. When diagnosed early, Chlamydia infections can be treated with antibiotics. However, the high costs required to identify and treat individuals with mild or no symptoms limits the feasibility of this control strategy. Moreover, hosts can remain chronically infected despite chemotherapy, and some antibiotics may induce chlamydial persistence [4]. Thus, development of safe and effective vaccines represents a cost-effective approach that would have a greater impact on the high prevalence of Chlamydia infections and the prevention of severe long-term sequelae.Like all chlamydiae, Ct and Cpn have a unique biphasic developmental cycle alternating between an infectious metabolically inert elementary body (EB) and a replicating metabolically active reticulate body (RB). After entry into susceptible cells such as epithelial cells, macrophages, endothelial and smooth muscle cells, the EB remains within a nonacidified vacuole known as an inclusion, where it differentiates into a RB, which replicates by binary fission. The generated progeny differentiate back into EBs that are then released upon host cell lysis to infect other cells. Under certain conditions, however, Chlamydia enters a persistent non-replicating stage but remains capable of resuming a productive cycle when the adverse *Corresponding author. Current mailing address: Intercell AG, Campus Vienna Biocenter 6, 1030 Wien, Austria. Phone: +43-1-20620-174. Fax: +43-1-20620-805. E-mail: bwizel@intercell.com. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Evidence of a role for CD8 + T cells in the immune control of ChlamydiaAn intact T cell compartment is required for resistance against Chlamydia infection. T ...